Related Experiment Video
Updated: Jul 14, 2026

23:56
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Screening for cervical cancer in an African setting
1Department of Obstetrics and Gynecology, University of the Free State, Bloemfontein 9300, South Africa. gnoghsc.md@mail.uovs.ac.za
Summary
Cervical cancer screening with Papanicolaou (Pap) smears decreased by 42% in South Africa's Free State province between 1985 and 2002. This decline suggests challenges in widespread cervical neoplasia screening in Africa.
Area of Science:
- Public Health
- Epidemiology
- Gynecologic Oncology
Background:
- Cervical neoplasia remains a significant health concern for women globally.
- Effective screening programs, such as those utilizing Papanicolaou (Pap) smears, are crucial for early detection and prevention.
- Assessing screening rates over time is vital for evaluating public health interventions.
Purpose of the Study:
- To determine the proportion of women screened for cervical neoplasia using Pap smears in South Africa's Free State province in 2002.
- To compare 2002 screening rates with those from a similar study conducted in 1985 to assess progress or decline.
Main Methods:
- A cross-sectional survey was conducted.
- Data were collected from 1887 Pap smears, representing 5% of smears processed by 7 laboratories in the Free State in 2002.
Main Results:
- In 2002, only 4.1% of women aged 15-65 in the Free State received Pap smears.
- Screening rates differed significantly by race: 18.8% for white women versus 2.6% for black women.
- Cervical cancer screening rates decreased by 42% from 1985 to 2002, indicating a significant decline in service provision.
Conclusions:
- The study documented a substantial deterioration in cervical screening services in the Free State province.
- The findings raise concerns about the feasibility and success of Pap smear screening programs in the African context.
- Urgent interventions are needed to reverse the declining trend in cervical cancer screening.
